Skip to Content

PGIM Jennison Health Sciences C PHLCX

Medalist Rating as of | See PGIM Investment Hub
  • NAV / 1-Day Return 18.35  /  +1.38 %
  • Total Assets 1.8 Bil
  • Adj. Expense Ratio
    1.980%
  • Expense Ratio 1.980%
  • Distribution Fee Level Average
  • Share Class Type Level Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield
  • Turnover 64%

USD | NAV as of Feb 22, 2024 | 1-Day Return as of Feb 22, 2024, 11:17 PM GMT+0

Morningstar’s Analysis PHLCX

Will PHLCX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Bold, yet appealing.

Senior Analyst Chris Tate

Chris Tate

Senior Analyst

Summary

PGIM Jennison Health Sciences’ deep domain expertise and distinctive approach make for an attractive healthcare offering.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PHLCX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 53.1
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

11.01 187.0 Mil
Healthcare

Merck & Co Inc

7.49 127.2 Mil
Healthcare

UnitedHealth Group Inc

6.43 109.1 Mil
Healthcare

AbbVie Inc

5.25 89.1 Mil
Healthcare

Vertex Pharmaceuticals Inc

4.75 80.7 Mil
Healthcare

Apellis Pharmaceuticals Inc

4.51 76.6 Mil
Healthcare

Novo Nordisk A/S ADR

4.17 70.8 Mil
Healthcare

Becton Dickinson & Co

3.31 56.2 Mil
Healthcare

The Cigna Group

3.11 52.7 Mil
Healthcare

Boston Scientific Corp

3.03 51.4 Mil
Healthcare